Spasticity, as a result of cortical motor neuron injury, is a frequent symptom in neurological disorders. Tolperisone is a centrally acting muscle relaxant, which has been used for 50 years in clinical practice. Tolperisone has a membrane-stabilising effect and it inhibits voltage-gated sodium and calcium channels. Although it targets the central neural system, it has no sedative side effects, in contrast to other muscle relaxants. Besides clinical experiences of past decades, the efficacy of tolperisone has also been proved in a study fulfilling evidencebased criteria. In this double-blind, placebo-controlled, randomised, parallel group study, 78.3% of tolperisone-treated patients had an at least one-point reduction on the Asworth scale (a 5-grade scale used the measure spasticity), compared with 45% in the placebo-treated group. The excellent tolerability of tolpe-risone is demonstrated by the finding that the number of adverse events was greater in the placebo group than in the tolpe-risone group. Taking these facts in consideration, tolperisone is a safe and effective drug to treat' spasticity.
|Number of pages||4|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Oct 1 2011|
ASJC Scopus subject areas